Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer
Crawford ED1, Stone NN2, Yu EY3, Koo PJ4, Freedland SJ5, Slovin SF6, Gomella LG7, Berger ER8, Keane TE9, Sieber P10, Shore ND11, Petrylak DP12; the Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group. Urology. 2014 Jan 8. pii: S0090-4295(13)01371-X. doi: 10.1016/j.urology.2013.10.026. [Epub ahead of print]

Author information

1University of Colorado, Denver-Aurora, CO. Electronic address: 2Icahn School of Medicine at Mount Sinai, New York, NY. 3Fred Hutchinson Cancer Research Center, Seattle, WA. 4University of Colorado School of Medicine, Denver, CO. 5Durham VA and Duke University, Durham, NC. 6Memorial Sloan-Kettering Cancer Center, New York, NY. 7Thomas Jefferson University, Philadelphia, PA. 8Oncology Consortium, Scottsdale, AZ. 9Medical University of South Carolina, Charleston, SC. 10Lancaster Urology, Lancaster, PA. 11Carolina Urologic Research Center, Myrtle Beach, SC. 12Yale University Cancer Center, New Haven, CT; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group, University of Colorado Hospital, University of Colorado at Denver, Aurora, CO.


Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer.